CPRX - カタリスト・ファ―マシュ―ティカルズ (Catalyst Pharmaceuticals Inc.)

CPRXのニュース

   Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Position Raised by Geode Capital Management LLC  2021/11/07 10:00:41 Dakota Financial News
Geode Capital Management LLC raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 5.5% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 1,864,633 shares of the biopharmaceutical companys stock after buying an additional 97,768 shares during the quarter. Geode Capital Management LLC owned approximately 1.81% of Catalyst []
   Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Caxton Associates LP  2021/10/30 15:16:45 Dakota Financial News
Caxton Associates LP increased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 74.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 43,023 shares of the biopharmaceutical companys stock after acquiring an additional 18,431 shares during the period. []
   Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021  2021/10/25 12:03:00 Intrado Digital Media
The Company will host a Conference Call and Webcast on November 10, 2021, at 8:30 AM EST The Company will host a Conference Call and Webcast on November 10, 2021, at 8:30 AM EST
   Strength Seen in Catalyst (CPRX): Can Its 6.9% Jump Turn into More Strength?  2021/10/08 12:58:44 FXNews24
Catalyst Pharmaceutical CPRX shares soared 6.9% in the last trading session to close at $6.54. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stocks 21% gain over the past four weeks. Shares of Catalyst Pharmaceuticals have been surging consistently, following positive [] The post Strength Seen in Catalyst (CPRX): Can Its 6.9% Jump Turn into More Strength? appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .
   The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs  2021/10/08 11:31:17 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS ) Bicycle Therapeutics plc (NASDAQ: BCYC ) (announced interim Phase 1 data for BT5528 and preliminary results from Phase 1 study of BT8009) Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX ) Cytokinetics, Incorporated (NASDAQ: CYTK ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) Legend Biotech Corporation (NASDAQ: LEGN ) Click here for accessing Benzinga''s FDA Calendar Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 7) Acutus Medical, Inc. (NASDAQ: AFIB ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Amgen Inc. (NASDAQ: AMGN ) ( announced neurodegenerative disease drug collaboration with Nuemora) Angion Biomedica Corp. (NASDAQ: ANGN ) Applied DNA Sciences, Inc. (NASDAQ: APDN ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Avenue Therapeutics, Inc.
   Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer  2021/07/06 12:03:00 Intrado Digital Media
CORAL GABLES, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced the appointment of Dr. Preethi Sundaram as Chief Product Development Officer. This position will report to the Chief Executive Officer.
   Catalyst Pharmaceuticals Appoints Pharmaceutical Executive  2021/07/03 10:47:00 Intrado Digital Media
Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors GlobeNewswire
   Catalyst Pharmaceuticals Announces Exclusive License and  2021/07/02 02:16:30 Intrado Digital Media
Catalyst Pharmaceuticals Announces Exclusive License and Supply Agreement with DyDo Pharma for the Development and Commercialization GlobeNewswire
   Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors - Stocks News Feed  2021/06/29 12:03:00 Stocks News Feed
CORAL GABLES, Fla., June 29, 2021 (GLOBE NEWSWIRE) Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced the appointment of Molly Harper to the Companys Board of Directors. On behalf of the Board of Directors, Read More »Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors
   Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors  2021/06/29 12:03:00 Intrado Digital Media
CORAL GABLES, Fla., June 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced the appointment of Molly Harper to the Companys Board of Directors.
   Catalyst Pharmaceuticals, Inc.''s and KYE Pharmaceuticals'' Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®  2021/06/03 19:09:00 Benzinga
MISSISSAUGA, ON , June 3, 2021 /CNW/ - Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX ) , a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases , and KYE Pharmaceuticals Inc. ("KYE"), a private company headquartered in Mississauga, Ontario and focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, today announced a positive decision in their lawsuit in Canadian Federal Court challenging Health Canada''s approval of Medunik''s New Drug Submission (NDS) for Ruzurgi ® . The lawsuit sought judicial review of Health Canada''s decision to approve the NDS for Ruzurgi ® (Jacobus Pharmaceutical''s amifampridine product distributed in Canada by Medunik) and issue a Notice of Compliance ("NOC") on August 10, 2020 , as unreasonable due to Ruzurgi ® ''s product monograph and NDS explicitly referencing data included in Firdapse ® ''s NDS, approved
   Catalyst Pharmaceuticals, Inc.s and KYE Pharmaceuticals Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi  2021/06/03 17:20:00 Wallstreet:Online
- Without an NOC, Ruzurgi is without a Marketing Authorization in Canada - Matter Remanded Back to Health Canada to Provide a More Transparent Record of Its Decision in Light of Firdapses Data Protection CORAL GABLES, Fla., June 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on
   Catalyst: An A+ Quant Call, On The Edge  2021/06/03 07:26:48 Seeking Alpha
   Catalyst Pharmaceuticals, Inc.''s and KYE Pharmaceuticals'' Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi  2021/06/03 00:00:00 BioSpace
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), and KYE Pharmaceuticals Inc. ("KYE"), today announced a positive decision in their lawsuit in Canadian Federal Court challenging Health Canada''s approval of Medunik''s New Drug Submission (NDS) for Ruzurgi®.
   Catalyst Pharmaceuticals, Inc.s and KYE Pharmaceuticals Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®  2021/06/03 00:00:00 BioSpace
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), and KYE Pharmaceuticals Inc. ("KYE"), today announced a positive decision in their lawsuit in Canadian Federal Court challenging Health Canadas approval of Meduniks New Drug Submission (NDS) for Ruzurgi®.

calendar